# Revolution Medicines, Inc. Common Stock (RVMD) — Stock CV

Revolution Medicines, Inc. is a $40.7B healthcare company. It holds more cash than debt.

> Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers.

## Identity

- **Ticker**: RVMD
- **Sector**: Healthcare
- **Industry**: Biological Products, (No Diagnostic Substances)
- **Headquarters**: REDWOOD CITY, CA
- **Employees**: 883
- **Website**: https://www.revmed.com
- **Market cap**: $40.7B
- **Last price**: $189.76
- **Financial profile**: Mixed

## Vitals (TTM)

- **Revenue**: $0
- **Net income**: -$3.45B
- **Free cash flow**: -$2.65B
- **Net cash**: $2.75B

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 20 |
| Growth | 0 |
| Profitability | 0 |
| Health | 75 |
| Quality | 0 |
| Moat | 0 |

## Qualifications (beginner checklist) — 3 of 8 passed

- [ ] Profitable — -$3.45B TTM
- [x] Profit growing — +39.7% YoY
- [ ] Generates cash — -$2.65B TTM
- [x] Debt under control — more cash than debt
- [x] Established company — $40.7B market cap
- [ ] Not printing shares — +37.9% shares over ~5y
- [ ] Proven track record — 0/7 profitable years
- [ ] Financially stable — health score 50/100

## Strengths

- Net cash position after subtracting debt from cash

## Watch-outs

- Not profitable — 2833.9% net margin
- Negative free cash flow (-$2.7B)
- Loss-making in 6 of the recent years

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2022 | $79.7M | -$617M | -$578M |
| FY2023 | $40.3M | -$946M | -$790M |
| FY2024 | $0 | -$1.37B | -$1.45B |
| FY2025 | $0 | -$2.57B | -$2.18B |
| FY2026 | — | -$1.55B | -$1.10B |

---

Source: https://stockcv.com/RVMD — derived from company filings; may be delayed or incomplete. Information, not investment advice.